FIT Biotech Oy
Company release December 27, 2017 at 4.30 pm
FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself without payment
FIT Biotech Oy's (Company) Board of Directors has resolved December 27, 2017 to issue 80,000,000 K-shares without payment to the Company itself based on the authorization granted by the extraordinary general meeting on December 14, 2017.
The purpose is mainly to use the shares to implement the new Alpha Blue Ocean funding programme, disclosed on December 23, 2017.
FIT BIOTECH OY
Board of Directors
For further information:
Chairman of the Board of Directors Rabbe Slätis
Tel: +358 40 840 6749
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
NASDAQ OMX Helsinki